Core iPSC Generation and QC
- One-clone expansion (3 vials)
- Morphology
- Mycoplasma testing
- Core pluripotency panel (qPCR)
- EB formation
Best suited for: Routine research and early feasibility.
What is iPSC reprogramming?
iPSC reprogramming is the process of converting an adult (somatic) cell — such as a urine-derived cell, fibroblast, or PBMC — into an induced pluripotent stem cell capable of self-renewal and differentiation into most cell types. abm's service uses mRNA-based reprogramming to generate research-ready, patient-specific iPSC lines from donor-derived cells.
What starting materials can abm reprogram?
abm supports urine-derived cells, fibroblasts, and PBMCs, subject to feasibility and sample-acceptance review. Other somatic cell types may be considered for custom projects.
What species are supported for reprogramming?
Our standard reprogramming service is designed for human-derived cells. If your project involves cells from another species, contact our team to discuss whether a custom approach may be suitable.
Why should I consider urine-derived cells?
Urine collection is non-invasive and repeatable and does not require a skin biopsy or blood draw. Established, healthy urine-derived cultures are also compatible with integration-free iPSC reprogramming.
How does reprogramming efficiency vary between urine-derived cells, fibroblasts, and PBMCs?
Reprogramming performance can vary by starting cell type, donor biology, cell quality, passage number, culture history, and experimental conditions. Urine-derived epithelial cells may offer workflow advantages because they already have an epithelial phenotype, while fibroblasts undergo a mesenchymal-to-epithelial transition during reprogramming. Our team reviews your starting material before confirming project scope and feasibility.
How many clones will I receive?
The standard scope includes one independent validated clone with three cryovials. Additional clones and vials are available as add-ons.
What quality control is included?
The standard service includes morphology, mycoplasma testing, a core pluripotency panel by qPCR, and EB formation. Karyotyping, Human Cell Line Authentication, pluripotency markers by IF, trilineage differentiation by IF, and additional qPCR markers are available as add-ons.
Can abm create gene-edited or differentiated models from my iPSCs?
Yes. Optional downstream services may include gene editing, isogenic control generation, directed differentiation, organoid development, and application-specific characterization.
Are the generated iPSCs intended for clinical use?
No. Unless separately stated in an executed agreement, service outputs are for research use only and are not intended for diagnostic, therapeutic, or clinical applications.